Acutaas Chemicals' audit record is clean on its face: five consecutive years of unqualified opinions, no fraud findings, and a stable auditor since 2018. The record that needs attention sits around the edges: related-party lending to subsidiaries has ballooned to ₹147.85 crore, a 10% stake in a subsidiary was handed to a business partner with no disclosed valuation, and executive pay is rising against repeated institutional dissent.
Key findings
- Related-party loans to subsidiaries jumped from ₹0.21 crore to ₹147.85 crore, and a 10% stake was given away with no disclosed value
Major- Loans under Section 186 rose from ₹0.21 crore in FY2022-23 to ₹140.7 crore to Acutaas Advance Material Limited in FY2025-26. The company seeks shareholder approval for material related-party transactions with ACEPL up to ₹290 crore, against that subsidiary's FY2025-26 turnover of ₹0.02 crore and net worth of (₹58.3) million. Management confirms a 10% stake in the electrolyte subsidiary was given to business partner "ARZ" for business development services, with no valuation, consideration, or timing of the original agreement disclosed. - The group has layered new subsidiaries and a ₹200 crore South Korean JV, with operating subsidiaries persistently loss-making
Major- Acutaas Chemicals Electrolytes reported revenue of ₹0.02 crore and a loss of ₹3.73 crore in FY2025-26, while Acutaas Advance Material reported nil revenue and a loss of ₹2.12 crore. The wholly owned subsidiary AAML has invested approximately ₹200 crore in Indichem Inc., the South Korean step-down subsidiary that inaugurated its semiconductor chemicals plant on August 28, 2026. Indichem was identified as a Material Subsidiary in FY2025-26, a year after no subsidiaries met that threshold. - Executive pay rises while institutional shareholders dissent on remuneration resolutions
Major- Mr. Chetankumar Vaghasia's remuneration rose from ₹4.62 crore in FY2022-23 to ₹4.85 crore in FY2024-25, and was ₹6.42 crore in FY2025-26. At the 18th AGM on September 25, 2025, public institutional shareholders voted 42.41% against the reappointment and remuneration of both Mr. Patel and Mr. Vaghasia. Two insider-trading regulation violations by designated persons were identified during FY2025-26, with action taken by the Audit Committee. - The debt picture is clean on its face, but the collateral story shifted: secured working-capital facilities became "completely unsecured" in FY26
Major- The company reported nil secured bank borrowings as of March 31, 2026, and all facilities were completely unsecured. The same FY2024-25 notes disclosed working capital loans secured by hypothecation of Sachin Facility assets. Shareholders approved on April 13, 2024 an increase in borrowing powers to ₹500 crore and creation of charges up to ₹500 crore. No covenant breaches were reported in any year from FY2021-22 through FY2025-26. - Income-tax demands under appeal grew to ₹15.38 crore, and a ₹11.94 crore fire insurance claim sits in arbitration
Minor- Income-tax demands under appeal with CIT (Appeals) totalled ₹15.38 crore as at March 31, 2025, up from ₹2.70 crore in FY2022-23, with the largest single demand at ₹14.15 crore for AY 2022-23. A fire insurance claim of ₹11.94 crore was settled by New India Assurance at ₹7.62 crore, which the company accepted under protest; the Bombay High Court accepted the arbitration application on April 27, 2024. - Revenue quality is strained by a 90-360 day credit period and receivables that grew faster than sales
Minor- The company granted customers an average credit period of approximately 90-360 days in FY2025-26. Trade receivables rose 42.4% in one year, from Rs. 16,166.12 lakhs (₹161.66 crore) as at 31 March 2022 to Rs. 23,026.11 lakhs (₹230.26 crore) as at 31 March 2023, with receivables aged 6 months to 1 year nearly tripling. Receivable days improved to 98.80 in FY2025-26 from 105 in FY2024-25. - Cash generation has improved but remains uneven, and heavy capex has been funded by equity raises
Minor- Cumulative CFO of ₹659 crore against cumulative EBITDA of ₹1,232 crore over ten years gives a CFO/EBITDA ratio of 0.54x. Free cash flow was negative at -₹76.30 crore in FY2025 and -₹190 crore in FY2024. The company raised ₹500 crore in FY2024-25 via QIP and preferential allotment, with QIP proceeds fully utilised and no deviation from stated objects. - The Ami Oncotheranostics JV was fully impaired in FY2024, with no PPE impairments recorded in any year
Minor- The company fully impaired its investment in the Ami Oncotheranostics LLC joint venture in FY2024 as an exceptional item, citing the research nature and uncertain success rate. No impairment provision on property, plant and equipment was recorded in any year from FY2021-22 through FY2025-26. - Five consecutive years of unqualified opinions and clean CARO responses, with one audit-trail gap that was remediated
Clean- Maheshwari & Co. issued unqualified opinions on both standalone and consolidated financial statements for each year from FY2021-22 through FY2025-26. The FY2023-24 reports noted the audit trail was not enabled at the database level, but the FY2024-25 and FY2025-26 reports confirmed the feature operated throughout the year with no tampering. CARO reported no fraud, no wilful default, and no benami property proceedings in any year reviewed. - Auditor continuity is stable, with Maheshwari & Co. serving since 2018 and reappointed through 2028
Clean- Maheshwari & Co. was originally appointed at the 11th AGM on May 26, 2018 and reappointed for a second five-year term from September 25, 2023 until the 21st AGM in 2028. No resignation of statutory auditors occurred in any year from FY2021-22 through FY2025-26. The signing partner changed from K.K. Maloo in FY2021-22 to Pawan Gattani in FY2022-23 to Vikas Asawa from FY2023-24 through FY2025-26.
What to watch
- ₹290 crore RPT limit with ACEPL. The approval, valid from the 19th AGM to the 20th AGM, will be tested against ACEPL's negative net worth of (₹58.3) million as of FY2025-26.
- Insurance arbitration. The Sole Arbitrator appointed by the Bombay High Court is hearing the dispute with New India Assurance, as of the FY2023-24 Annual Report.
- Income-tax assessment. The Section 143(3) order for FY 2021-22, received December 12, 2024, carries a principal tax liability of approximately ₹10.20 crore; the company is evaluating appeal and rectification.
- Indichem ramp-up. The South Korean plant was inaugurated August 28, 2026; its first financial statements and revenue contribution from the ₹200 crore investment will appear in FY2026-27.
Bottom line: This is an audited record with clean opinions, stable auditor tenure, and no fraud findings across five years. The risk character is one of opacity around related-party fund flows and group expansion: loans to subsidiaries have grown to ₹147.85 crore, a subsidiary stake was transferred with no disclosed value, and a ₹200 crore JV has yet to generate revenue. Watch the 19th AGM votes on the ₹290 crore RPT limit and the reappointment resolutions, and track whether Indichem's operational ramp-up justifies the investment.